ESA product use, by DOPPS country and cross-section

		Epoetin only		Darbepoetin only		Mircera only		Other
		N Ptnts	Wgtd %	N Ptnts	Wgtd %	N Ptnts	Wgtd %	N Ptnts	Wgtd %
DOPPS Country	DOPPS Cross-section	140	62.2%	79	37.8%	.	.	.	.
AusNZ	D4(2010)	140	62.2%	79	37.8%	.	.	.	.
Belgium	D4(2010)	129	40.1%	180	44.4%	62	15.5%	.	.
Canada	D4(2010)	135	41.6%	124	58.4%	.	.	.	.
France	D4(2010)	57	18.8%	169	56.1%	55	25.0%	.	.
Germany	D4(2010)	251	59.4%	131	28.1%	30	7.2%	28	5.3%
Italy	D4(2010)	212	61.7%	101	29.7%	30	8.6%	.	.
Japan	D4(2010)	648	48.8%	650	50.7%	.	.	4	0.5%
Spain	D4(2010)	248	52.5%	153	32.9%	58	14.0%	4	0.6%
Sweden	D4(2010)	258	67.8%	112	31.1%	3	1.2%	.	.
UK	D4(2010)	116	46.9%	164	45.8%	28	7.4%	.	.
US	D4(2010)	2,597	93.9%	123	6.1%	.	.	.	.

Medications reported as prescribed (not necessarily taken) in previous 3 months, among treated patients